Sugi Predict

Sugi Predict / Compounds / SCHEMBL640529

SCHEMBL640529

SCHEMBL640529

COC(=O)C(c1ccccc1OC)n1c(=O)n(C(=O)O)c2ccc(Cl)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 4/20 0.39
▸ L3MBTL1 Q9Y468 4/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ GRIK1 P39086 1/20 0.37
▸ LMNA P02545 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ S1PR2 O95136 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ NR3C2 P08235 1/20 0.36
▸ MAPK8 P45983 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ KCNMA1 Q12791 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ SHMT2 P34897 1/20 0.35
▸ CTSA P10619 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639820 0.87 LMNA (0.38) LPAR1L3MBTL1LMNAMAPTS1PR2
SCHEMBL640324 0.81 MEN1 (0.41) L3MBTL1GRIK1LMNAMAPTSMN1; SMN2
SCHEMBL641063 0.79 LMNA (0.42) L3MBTL1NPSR1ALDH1A1LMNAPTGDR2
SCHEMBL639969 0.76 MEN1 (0.48) L3MBTL1NPSR1ALDH1A1LMNAMAPT
SCHEMBL640979 0.70 CBX7 (0.44) ALDH1A1GAA
SCHEMBL640150 0.69 MDM2 (0.46) L3MBTL1NPSR1ALDH1A1LMNAMAPT
SCHEMBL642977 0.66 LMNA (0.44) L3MBTL1ALDH1A1LMNAMAPK8SMN1; SMN2
SCHEMBL10500938 0.66 LMNA (0.50) LPAR1L3MBTL1NPSR1ALDH1A1LMNA
SCHEMBL641167 0.65 L3MBTL1 (0.48) L3MBTL1NPSR1ALDH1A1LMNAMAPT
SCHEMBL639976 0.65 LMNA (0.60) L3MBTL1NPSR1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 — — US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 — — US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 — — US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A LPAR1 3915/4885L3MBTL1 3180/4885NPSR1 105/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A LPAR1 3915/4885L3MBTL1 3180/4885NPSR1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.